Paolo Meoni

This inventor holds 1 USPTO granted patent. Top assignee: Sanofi. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paolo Meoni. Retrieved from https://idiyas.com/inventor/paolo-meoni-0edinkyg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Paolo Meoni: Innovator in Immunology

Introduction

Paolo Meoni is a distinguished inventor known for his contributions to the field of immunology. He has made significant strides in developing innovative solutions that target critical areas in medical science. His work is particularly focused on immunoglobulin single variable domains.

Latest Patents

Paolo Meoni holds a patent titled "Polypeptides Comprising Immunoglobulin Single Variable Domains Targeting Glypican-3 and T Cell Receptor." This patent represents a notable advancement in the understanding and treatment of diseases related to glypican-3 and T cell receptors.

Career Highlights

Meoni is currently employed at Sanofi, a global healthcare company dedicated to supporting people through their health challenges. His role at Sanofi allows him to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Throughout his career, Paolo has worked alongside notable colleagues, including Daniel Janssen and Carlo Boutton. These collaborations have fostered an environment of innovation and have led to significant advancements in their respective fields.

Conclusion

Paolo Meoni's work exemplifies the spirit of innovation in the medical field. His contributions, particularly in immunology, continue to pave the way for future advancements in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…